SCLX Q2 2024 Earnings — Scilex Holding Company Revenue & Financial Results | Market Cap Arena

SCLXScilex Holding Company

$73M

Q2 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$16M+30.1% YoY

Gross Profit

$12M73.2% margin

Operating Income

-$16M-95.4% margin

Net Income

-$38M-229.6% margin

EPS (Diluted)

$-10.94

QoQ Revenue Growth

+50.4%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$105M

Total Liabilities

$319M

Stockholders' Equity

-$215M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$13M	+30.1%
Gross Profit	$12M	$8M	+42.5%
Operating Income	-$16M	-$23M	+31.5%
Net Income	-$38M	-$27M	-41.0%